Expression levels of cell-cycle markers such as CDK4 and cyclin B1 were also found to be reduced in both the cancer cell lines as a result of treatment with KRAS G12C inhibitors or their combinations with selinexor (Fig. 5B). Here, KRAS is linked to cancer.